17β-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2559-2566

  Shulman, Lee P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hormone therapy; Menopause; Oestrogen; Progestin; Transdermal

Indexed keywords

ACRYLIC ACID; CALCIUM; CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTROGEN; ESTRONE; LEVONORGESTREL; LIPID; MEDROXYPROGESTERONE ACETATE; POLYETHYLENE; POLYMER; PROGESTERONE; VITAMIN D; CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ACCIDENT; ADULT; AMENORRHEA; AREA UNDER THE CURVE; ARTICLE; ATROPHY; BACKACHE; BIOEQUIVALENCE; BODY WEIGHT DISORDER; BREAST CANCER; CANDIDIASIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; EDEMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FLATULENCE; HEADACHE; HORMONAL THERAPY; HUMAN; LIPID BLOOD LEVEL; MASTALGIA; MENOPAUSAL SYNDROME; MENTAL INSTABILITY; OUTCOMES RESEARCH; PUBLICATION; QUALITY OF LIFE; QUESTIONNAIRE; SINGLE DRUG DOSE; SINUSITIS; SKIN MANIFESTATION; SKIN PENETRATION; SYMPTOMATOLOGY; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; UTERUS; VAGINA BLEEDING; VAGINITIS; VASOMOTOR DISORDER; WEIGHT GAIN; DRUG EFFECT; MENOPAUSE;

CONTRACEPTIVE AGENTS, FEMALE; ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; MENOPAUSE;

EID: 10644253700     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2559     Document Type: Article

References (19)

1. ROUSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
2. ANDERSON GL, LIMACHER M, ASSAF AR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 291(14):1701-1712.
3. SHULMAN LP, YANKOV V, UHL K: Safety and efficacy of a continuous once-a-week 17β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause (2002) 9(3 ):195-207.
4. THE WRITING GROUP FOR THE PEPI TRIAL: Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA (1995) 273(3):199-208.
5. MILLION WOMEN STUDY COLLABORATORS: Patterns of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG (2002) 109(12):1319-1330.
6. BERAL V AND THE MILLION WOMEN STUDY COLLABORATORS: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 362(9382):419-427.
7. HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA (1998) 280(7 ):605-613.
8. VALIMAKI MJ, LAITINEN KA, TAHTELA RK, HIRVONEN EJ, RISTELI JP: The effects of transdermal estrogen therapy on bone mass and turnover in early postmenopausal smokers: a prospective, controlled study. Am. J. Obstet. Gynecol. (2003) 189(5):1212-1220.
9. HEMELAAR M, VAN DER MOOREN MJ, MIJATOVIC V et al.: Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study. Menopause (2003) 10(6):5555-5558.
10. GIRDLER SS, HINDERLITER AL, WELLS EC, SHERWOOD A, GREWEN KM, LIGHT KC: Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects. Obstet. Gynecol. (2004) 103(1):169-180.
11. CSIZMANDI I, COLLET JP, BENEDETTI A, BOIVIN JF, HANLEY JA: The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. Br. J. Cancer (2004) 90(1):76-81.
12. STEVENSON JC, OLADIPO A, MANASSIEV N, WHITEHEAD MI, GUILFORD S, PROUDLER AJ: Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular markers. Br. J. Haematol. (2004) 124(6):802-808.
13. SCARABIN P-Y, OGER E, PLU-BUREAU G et al.: Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet (2003) 362(9382 ):428-432.
14. HAAS JS, KAPLAN CP, GERSTENBERGER EP, KERLILOWSKE K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann. Intern. Med. (2004) 140 (3):181-188.
15. UTIAN WH, SHOUPE D, BACHMANN G, PINKERTON JV, PICKAR JH: Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil. Steril. (2001) 75(6):1010-1079.
16. PICKAR JH, YEH I, WHEELER JE, CUNNANE MF, SPEROFF L: Endometrial effects of lower doses of conjugated equine estrogen and medroxyprogesterone acetate. Fertil. Steril. (2001) 76 1):25-31.
17. LINDSAY R, GALLAGHER JC, KLEERKOPER M, PICKAR JH: Effect of lower doses of conjugated equine estrogen with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA (2002) 287(20):2626-2676.
18. Berlex Laboratories: Climara Pro™ (estradiol/levonorgestrel transdermal system) package insert. Berlex laboratories, USA (2003).
19. ETTINGER B, ENSRUD KE, WALLACE R et al.: Effects of ultra low-dose transdermal estradiol on bone mineral density: results of a randomized clinical trial. Obstet. Gynecol. (2004) 104 3):443-451.